Apatinib plus immunotherapy for tough childhood neuroblastoma
Part of Cancer clinical trials.
This trial studies whether apatinib, a targeted medicine, combined with an immunotherapy treatment can shrink or control neuroblastoma that has come back or does not respond to prior treatment. Because it is a Phase I/II single-group study, everyone receives the planned treatment and researchers watch side effects and response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is age 5 to 18 years old, with confirmed neuroblastoma on tissue testing
- Disease has returned or not responded to first-line treatment
- Expected survival is more than 12 weeks and the child can likely attend frequent visits
- Performance status is good (ECOG 0 to 1) and there are measurable tumors on CT
- Blood counts and organ tests during screening are safe enough for treatment
- Must be past the required waiting times after prior chemo, immunotherapy, radiation, or stem cell treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two experimental drugs for people with neuroblastoma or other solid tumors that have not responded to standard treatment. APG-115 is given alone or with APG-2575 to see if it can shrink tumors and help patients feel better.
This Phase 2 trial studies a targeted treatment approach for children and young adults with advanced neuroblastoma (a childhood cancer). It may help by using lab-tested cancer features to guide therapy after initial treatment and transplant.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.